24 filings
8-K
ADXS
Ayala Pharmaceuticals, Inc.
20 Dec 19
Advaxis Reports Fiscal Year 2019 Financial Results and Provides a Business Update
4:31pm
8-K
ADXS
Ayala Pharmaceuticals, Inc.
25 Oct 19
Advaxis Announces Business and Pipeline Update
12:00am
8-K
ADXS
Ayala Pharmaceuticals, Inc.
4 Oct 19
Other Events
4:31pm
8-K
ADXS
Ayala Pharmaceuticals, Inc.
13 Sep 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
ADXS
Ayala Pharmaceuticals, Inc.
9 Sep 19
Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline Update
4:30pm
8-K
wxt7bvnxaew29ysqge5
6 Sep 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
r1dq9zjf
22 Aug 19
Advaxis, Inc. Issues Letter to Shareholders
4:15pm
8-K
fer14alp8v5n lxl
31 Jul 19
Material Modifications to Rights of Security Holders
4:15pm
8-K
5i7 5rrz5
25 Jul 19
Advaxis, Inc. Announces Pricing of $16 Million Public Offering
5:19pm
8-K
ubk53z vvzit2oumno4
15 Jul 19
Other Events
9:38am
8-K
aeiohg80dgsd6dy
27 Jun 19
Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of its Phase 3 AIM2CERV Study
4:30pm
8-K
dqtic0ieim4
10 Jun 19
Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update
5:28pm
8-K
y5zj1a
15 May 19
Other Events
10:00am
8-K
t3rr7842gvm2lv 4h9
13 May 19
Advaxis Announces Appointment of Dr. Robert Petit to Chair of Scientific Advisory Board and Departure as Chief Scientific Officer
4:30pm
8-K
u0ncbi5xb5
15 Apr 19
Other Events
12:01pm
8-K
okwiyxsy3098 98ft2x
5 Apr 19
Entry into a Material Definitive Agreement
4:05pm
8-K
ehchueqo
29 Mar 19
Material Modifications to Rights of Security Holders
4:00pm
8-K
8i6041l
15 Mar 19
Material Modifications to Rights of Security Holders
4:00pm
8-K
wytz8janzkh
14 Mar 19
Entry into a Material Definitive Agreement
9:30am
8-K
z2hio3g69flgg5 mbai
12 Mar 19
Advaxis Reports First Quarter Fiscal 2019 Financial Results and Provides Clinical Pipeline Update
4:30pm